Details of Disease

General Information of Disease (ID: DISANFJN)

Disease Name	Poliomyelitis
Synonyms	infantile paralysis; Polia; poliomyelitis; acute poliomyelitis; polio
Disease Class	1C81: Acute poliomyelitis
Definition	An acute infectious disorder that affects the nervous system. It is caused by the poliovirus. The virus spreads by direct contact, and can be prevented by prophylaxis with the polio vaccine.
Disease Hierarchy	DISF6XLX: Anterior horn disorder DISBV50J: Acute disease DISH6045: Viral infection of central nervous system DISH5X8Z: Acquired motor neuron disease DISEU9EO: Poliovirus infection DIS1KV65: Myelitis DISANFJN: Poliomyelitis
ICD Code	ICD-11 ICD-11: 1C81
Disease Identifiers	MONDO ID MONDO_0017373 MESH ID D011051 UMLS CUI C0032371 MedGen ID 18545 Orphanet ID 2912 SNOMED CT ID 398102009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Infanrix hexa	DM4DCZX	Approved in EU	Vaccine	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Shan 6	DMGSX7D	Phase 3	NA	[2]
JNJ-64152348	DM3DO3T	Phase 2	Vaccine	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
NECTIN4	TTPO9EG	Definitive	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NECTIN2	OTIE0W6O	moderate	Altered Expression	[5]
PVR	OT3N91T7	Strong	Biomarker	[6]
CPVL	OTOJL31C	Definitive	Biomarker	[7]
ELF4	OT167PR5	Definitive	Biomarker	[8]
LSM2	OTHL77NY	Definitive	Biomarker	[9]
------------------------------------------------------------------------------------

References

1	EU Approved Drug Products from EU Official Website.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT03566940) A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule. U.S. National Institutes of Health.
4	Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.Gene Ther. 2013 Mar;20(3):338-47. doi: 10.1038/gt.2012.44. Epub 2012 Jun 21.
5	In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status.J Immunother. 2018 May;41(4):190-200. doi: 10.1097/CJI.0000000000000205.
6	CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. J Biol Chem. 2017 Jun 23;292(25):10664-10671. doi: 10.1074/jbc.M117.782425. Epub 2017 Apr 26.
7	Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.Nat Commun. 2017 Aug 15;8(1):245. doi: 10.1038/s41467-017-00090-w.
8	Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003.Indian J Med Res. 2003 Dec;118:217-23.
9	Inhibition of U snRNP assembly by a virus-encoded proteinase.Genes Dev. 2007 May 1;21(9):1086-97. doi: 10.1101/gad.1535607.